Abstract Details

Title Patient-centered Outcome Measures as a Means of Measuring the Effect of Tumor-related Epilepsy on Quality of Life in Patients with High-grade Glioma

Topic Neuro-oncology

Presentation(s) Neuro-oncology Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 012

Objective

To evaluate whether generic (Patient-Reported Outcomes Measurement Information System, PROMIS) or disease-specific (Quality of Life in Epilepsy Inventory-31, [QOLIE-31] and Functional Assessment of Cancer Therapy-Brain, [FACT-Br]) patient-centered outcome measures can identify epilepsy-related changes in health-related quality of life (HRQOL) in patients with high-grade glioma (HGG).

Background

Tumor-related epilepsy (TRE) is common in patients with HGG and causes significant morbidity and mortality. HRQOL measures may be important outcomes in therapeutic trials for TRE, but their use requires additional knowledge given that symptom burden is inherent to HGG itself.

Design/Methods Patients with newly diagnosed HGG enrolled in a prospective natural history study of TRE. Subjects were asked to complete the FACT-Br, QOLIE-31, and 6 PROMIS inventories at baseline, 3, 6 and 9 months. Baseline and follow-up clinical data were collected including: age, radiation/chemotherapy therapy, medication use, and KPS. Subjects were classified as no-TRE, controlled TRE (cTRE) or refractory TRE (rTRE). Associations between performance scores on FACT-BR, PROMIS, and QOLIE-31 and seizure status were examined using mixed models for repeated measures.

Results

Fifty-three of 64 subjects completed at least one FACT-Br/PROMIS survey (139 events). Twenty-two completed QOLIE-31. Adjusted for clinical variables, subjects with cTRE had lower average anxiety scores (-5.2 point difference, CI [-9.3, 1.2]; p=0.04) and higher satisfaction with social role scores (4.6 point difference, CI [0.01, 9.7], p=0.05) than those with no-TRE. Subjects with rTRE had lower PROMIS global physical function (-5.7 point difference, CI [-9.4—1.9]; p=0.004) and lower overall QOLIE-31 (-9.4 point difference, CI [-14.6, 4.2]; p=0.0001) scores than cTRE.

Conclusions TRE was not associated with patient-reported worsening of emotional, physical, social or functional well-being as measured by PROMIS or FACT-Br. Subjects with rTRE had lower physical function scores and QOLIE-31 scores, as compared to cTRE subjects. These findings suggest that QOLIE-31 may be more sensitive to changes in HRQOL related to epilepsy concerns.

Authors/Disclosures
Thomas Wychowski, MD (University of Rochester) PRESENTER	Dr. Wychowski has nothing to disclose.
Jennifer N. Serventi, PA (University Of Rochester Medical Center)	Ms. Serventi has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Novocure.
Peggy Auinger (University of Rochester)	Ms. Auinger has nothing to disclose.
Andrea C. Wasilewski, MD (Givens Brain Tumor Center)	Dr. Wasilewski has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novocure. Dr. Wasilewski has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Servier Pharmaceuticals .
Joy E. Burke, MD (University of Rochester)	No disclosure on file
Nimish A. Mohile, MD, FAAN	The institution of Dr. Mohile has received research support from Novocure.
Gretchen L. Birbeck, MD, MPH, DTMH, FAAN (University of Rochester/CHET)	An immediate family member of Dr. Birbeck has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Various. Dr. Birbeck has a non-compensated relationship as a Ambassador for Zambia with RSTMH that is relevant to AAN interests or activities.

��ɫ��

��ɫ��